Impact of Insulin Sensitivity and β-Cell Function Over Time on Glycemic Outcomes in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE): Differential Treatment Effects of Dual Therapy

What Was Tested

The paper reports a study of Liraglutide, published as a randomized controlled trial.

To compare the effects of insulin sensitivity and β-cell function over time on HbA1c and durability of glycemic control in response to dual therapy.

Who Took Part

GRADE participants were randomized to glimepiride (n = 1,254), liraglutide (n = 1,262), or sitagliptin (n = 1,268) added to baseline metformin and followed for mean ± SD 5.0 ± 1.3 years, with HbA1c assessed quarterly and oral glucose tolerance tests at baseline, 1, 3, and 5 years.

How the Study Was Run

The design is described as randomized.

Because people in this Liraglutide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

What Was Measured

The subject headings attached to it are Hypoglycemic Agents, Diabetes Mellitus, Type 2, Insulin Resistance, Liraglutide, Glycated Hemoglobin, Metformin and Sitagliptin Phosphate.

What This Means in Plain Language

The paper is a randomized study of Liraglutide.

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2024 (Diabetes care), a journal based in United States.

More context: the Liraglutide compound page, all human trials.